- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.12.25 | 'Market's thinking is backwards': FDA's 1-trial approval plan would boost R&D spend, Jefferies says | ||
| 05.12.25 | Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA | ||
| 05.12.25 | Pfizer Ventures gets behind Chinese biotech's $100M series A to boost R&D hub's capability | ||
| 04.12.25 | FDA slaps hold on Denali's plans for phase 1 rare disease trial | ||
| 04.12.25 | Royalty pens $275M financing deal for Denali drug awaiting delayed FDA decision | ||
| 04.12.25 | Crescent waxes pipeline with $80M Kelun deal, bagging ADC to pair with PD-1xVEGF bispecific | ||
| 04.12.25 | AstraZeneca's latest amyloidosis pact with Neurimmune could reach $780M | ||
| 04.12.25 | FDA names Tracy Beth Hoeeg, fresh from vaccine safety probe, as acting head of drug center | ||
| 03.12.25 | FDA floats user fee cuts for early-stage US trials, additional fees for overseas development | ||
| 03.12.25 | Capricor's phase 3 win sets up 2nd approval attempt for Duchenne cell therapy | ||
| 03.12.25 | Pfizer-backed Triana scores $120M series B to take molecular glue degrader into clinic | ||
| 03.12.25 | Pharvaris clocks a pivotal win in race for rapid HAE relief, teeing up filing to challenge KalVista | ||
| 03.12.25 | Théa pens $280M deal for Iolyx's phase 3-ready dry eye disease drug | ||
| 03.12.25 | Muvon flexes muscle cell therapy data to challenge synthetic incontinence implants | ||
| 02.12.25 | CDER head Richard Pazdur set to retire shortly after appointment: Stat | ||
| 02.12.25 | FDA issues draft guidance to reduce primate testing for certain antibodies | ||
| 02.12.25 | Janux T-cell engager data sink stock, but analysts still see best-in-class potential | ||
| 02.12.25 | Tiziana to spin out IL-6 drug into new company, citing Big Pharma's interest in modality | ||
| 02.12.25 | Imvax takes brain cancer cell therapy to FDA, betting survival hit will overshadow primary miss | ||
| 01.12.25 | European Union teams up with Angelini to funnel €150M to European health startups | ||
| 01.12.25 | Regeneron makes $150M bet on Tessera's rare disease gene writing prospect | ||
| 01.12.25 | Akebia to pay $12M to Q32 Bio for centerpiece of rare kidney disease pipeline | ||
| 01.12.25 | Belite brings FDA filing into view with phase 3 Stargardt disease victory | ||
| 26.11.25 | Vaccine-focused Valneva consolidates R&D footprint by shuttering site, eliminating 30 roles | ||
| 26.11.25 | AI may be the key to reigniting VC interest in biotech: PitchBook |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .